Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.

Abstract

Giant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54 × 40 × 40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17 × 12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.

• Authors: Ertugrul Tasan, Hakan Hanimoglu, Seda Turgut, Mahmut Muzaffer Ilhan, Sevket Evran, Mehmet Yasar Kaynar
• Journal: Neuro endocrinology letters (Neuro Endocrinol Lett) Vol. 36 Issue 1 Pg. 28-30 ( 2015) ISSN: 0172-780X [Print] Sweden
• PMID: 25789596 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Ergolines
• Cabergoline

Topics

• Adult
• Antineoplastic Agents (administration & dosage, pharmacology)
• Cabergoline
• Ergolines (administration & dosage, pharmacology)
• Follow-Up Studies
• Humans
• Male
• Optic Chiasm (pathology)
• Pituitary Neoplasms (complications, drug therapy, pathology)
• Prolactinoma (complications, drug therapy, pathology)
• Treatment Outcome
• Vision, Low (drug therapy, etiology, physiopathology)